⌘K
t
On 23 January 2026, Genus plc announced that Canada approved the use of its innovative PRRS Resistant Pig (PRP) gene edit, following years of collaboration with Canadian regulatory agencies. A 2024 study cited within the announcement estimated the cost of PRRS at $1.2 billion per annum in the U.S., and a separate study indicated it increased antibiotic usage by over 200%.
| Date | 23 Jan 2026 |
| Time | 17:23:49 |
| Category | Miscellaneous |
| ID | 2366Q |
23 January 2026
Genus plc ("Genus" or the "Group")
PRP Regulatory Progress - Canada
This announcement contains inside information
Genus (LSE: GNS), a leading global animal genetics company, announces the following update in relation to its innovative PRRS1 Resistant Pig ("PRP") programme.
Genus is pleased to announce that Canada has approved use of the PRP gene edit. This approval follows years of close collaboration with multiple Canadian regulatory agencies and represents another important step towards PRP commercialisation in North America. Genus believes successful commercialisation of PRP in North America requires further approvals in key North American export markets, particularly Mexico and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China.
PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. A 2024 study from Iowa State University2 estimated the cost of PRRS to be $1.2 billion per annum in the U.S. alone and a separate study indicated that PRRS increased antibiotic usage by more than 200%3.
For further information please contact:
Genus plc Tel: +44 125 634 5970
Jorgen Kokke, Chief Executive Officer
Andy Russell, Chief Financial Officer
Anand Date, Investor Relations & Sustainability Director
Burson Buchanan Tel: +44 207 466 5000
Charles Ryland; Mark Court; Toto Berger; Jamie Hooper
The information contained within this announcement is deemed by Genus to constitute inside information as stipulated under the Market Abuse Regulation (EU) no. 596/2014 (as incorporated into UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). On the publication of this announcement via a regulatory information service, this inside information is now considered to be in the public domain. The person responsible for arranging the release of this announcement is Lucie Grant, Group General Counsel and Company Secretary.
About Genus
Genus is a world-leading animal genetics company. Genus creates advances in animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.
The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRP is a market leading innovation in gene editing, which Genus is looking to commercialise in the porcine industry once regulatory approval is gained.
With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.
Notes
1 Porcine Reproductive and Respiratory Syndrome
3 https://dr.lib.iastate.edu/entities/publication/4e3cd302-5ae9-4185-8ead-405e0d4ec2f2